フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
Karolinska Development Annual Report 2023 published STOCKHOLM, SWEDEN – March 22, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today...
Karolinska Development’s portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million STOCKHOLM, SWEDEN...
Karolinska Development’s portfolio company Biosergen publishes prospectus due to rights issue of units STOCKHOLM, Sweden, March 14 2024...
Karolinska Development’s portfolio company Umecrine Cognition presents preclinical Parkinson’s data on golexanolone at AD/PD STOCKHOLM, SWEDEN –...
Year-end Report - January-December 2023 STOCKHOLM – 16 February 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its...
Karolinska Development’s portfolio company AnaCardio secures SEK 50 million as part of its Series A investment round STOCKHOLM, SWEDEN...
Karolinska Development's portfolio company OssDsign reports exceptional clinical data for its nanosynthetic bone graft product...
Karolinska Development's portfolio company OssDsign expects fourth-quarter revenues to exceed market estimates STOCKHOLM, SWEDEN...
Karolinska Development’s portfolio company PharmNovo´s drug candidate PN6047 in a NIDA funded collaboration STOCKHOLM, SWEDEN, December 4...
Karolinska Development’s portfolio company Umecrine Cognition presents positive effects of golexanolone in a preclinical model of cholestasis...
Karolinska Development’s portfolio company Umecrine Cognition raises additional funding for the clinical development of golexanolone...
Interim Report - January-September 2023 STOCKHOLM – 17 November 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its...
Karolinska Development's portfolio company Modus Therapeutics raises capital to expand the development program for sevuparin STOCKHOLM...
Karolinska Development’s portfolio company PharmNovo reports positive results from a clinical phase 1 study of drug candidate PN6047...
Karolinska Development’s portfolio company PharmNovo reports promising preclinical results on abuse potential and withdrawal symptom relief for...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約